BIO-B
Bio-Rad Laboratories Inc
365.10$
+0.0%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +7.8% | -10.3% | +4.5% | +1.8% | +2.7% | -12.3% | +11.3% | +0.2% | +6.2% | -14.6% | +9.9% | – | |
| – | +6.4% | -9.8% | -0.6% | +3.9% | +10.8% | -14.2% | +9.6% | +1.1% | +12.4% | -18.8% | +8.0% | – | |
| – | +9.0% | -10.8% | +8.8% | +0.2% | -3.9% | -10.5% | +12.8% | -0.6% | +0.5% | -10.4% | +11.8% | – | |
| – | +42.9% | +2.8% | -7.3% | +53.4% | -12.5% | -7.7% | -17.7% | +17.9% | -7.9% | -4.3% | -2.7% | – | |
| – | +3.0% | +3.7% | -9.4% | +2.9% | +1.8% | +2.4% | -0.5% | -0.4% | +6.9% | -3.9% | -0.2% | – | |
| – | +9.6% | +2.4% | -7.6% | +14.9% | -2.7% | -0.5% | -5.0% | +3.7% | +1.5% | -2.5% | -0.8% | – | |
| – | +7.5% | -46.8% | +95.2% | -36.5% | -9.5% | -59.4% | +225.3% | -13.9% | -6.8% | -44.9% | +112.9% | – | |
| – | -0.3% | -0.7% | -0.1% | -0.7% | +0.1% | -1.5% | +5.0% | -2.4% | -1.6% | +1.7% | -1.6% | – | |
| – | +212.5% | +14.6% | -667.4% | – | -205.5% | – | +396.4% | -204.1% | – | -174.2% | – | – | |
| – | +155.1% | +36.2% | -679.3% | – | -192.6% | – | +395.9% | -192.7% | – | -177.8% | – | – | |
| – | +229.1% | +9.8% | -664.1% | – | -209.6% | – | +396.6% | -207.6% | – | -173.2% | – | – | |
| – | +149.9% | +11.6% | -594.9% | – | -191.8% | – | +257.5% | -176.4% | – | -164.1% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.